Aptamers as tools for target prioritization and lead identification

Drug Discovery Today

Volumn 7, Issue 24, 2002, Pages 1221-1228

  Burgstaller, Petra ^a   Girod, Anne ^a   Blind, Michael ^a  

^a NascaCell Technologies AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CELL PROTEIN; LEAD; LIGAND; NUCLEIC ACID;

DRUG IDENTIFICATION; DRUG SYNTHESIS; DRUG TARGETING; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROTEIN FUNCTION; REVIEW; TECHNOLOGY; VIRUS REPLICATION;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NUCLEIC ACIDS; REPRODUCIBILITY OF RESULTS;

EID: 0037114941     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02522-9     Document Type: Review

References (55)

1. Harris S., Foord S.M. Transgenic gene knock-outs: functional genomics and therapeutic target selection. Pharmacogenomics. 1:2000;433-443.
2. Schlingensiepen R., Schlingensiepen K.H. Antisense oligodeoxynucleotides-highly specific tools for basic research and pharmacotherapy. Schlingensiepen R., Brysch W. Antisense - From Technology to Therapy. 1997;3-28 Blackwell.
3. Fire A., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:1998;806-811.
4. Sharp P.A. RNA interference - 2001. Genes Dev. 15:2001;485-490.
5. Elbashir S.M., et al. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15:2001;188-200.
6. Hermann T., Patel D.J. Adaptive recognition by nucleic acid aptamers. Science. 287:2000;820-825.
7. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 249:1990;505-510.
8. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature. 346:1990;818-822.
9. Brody E.N., Gold L. Aptamers as therapeutic and diagnostic agents. J. Biotechnol. 74:2000;5-13.
10. Famulok M., et al. Nucleic acid aptamers-from selection in vitro to applications in vivo. Acc. Chem. Res. 33:2000;591-599.
11. Kensch O., et al. HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity. J. Biol. Chem. 275:2000;18271-18278.
12. Pagratis N.C., et al. Potent 2′-amino-, and 2′-fluoro-2′-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat. Biotechnol. 15:1997;68-73.
13. Ruckman J., et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273:1998;20556-20567.
14. Jayasena S.D. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 45:1999;1628-1650.
15. White R.R., et al. Developing aptamers into therapeutics. J. Clin. Invest. 106:2000;929-934.
16. Fitzwater T., Polisky B. A SELEX primer. Methods Enzymol. 267:1996;275-301.
17. Conrad R.C., et al. In vitro selection of nucleic acid aptamers that bind proteins. Methods Enzymol. 267:1996;336-367.
18. Marshall K.A., Ellington A.D. In vitro selection of RNA aptamers. Methods Enzymol. 318:2000;193-214.
19. Cox J.C., et al. Automated RNA selection. Biotechnol. Prog. 14:1998;845-850.
20. Cox J.C., Ellington A.D. Automated selection of anti-protein aptamers. Bioorg. Med. Chem. 9:2001;2525-2531.
21. Drolet D.W., et al. A high throughput platform for systematic evolution of ligands by exponential enrichment (SELEX). Comb. Chem. High Throughput Screen. 2:1999;271-278.
22. Bell S.D., et al. RNA molecules that bind to and inhibit the active site of a tyrosine phosphatase. J. Biol. Chem. 273:1998;14309-14314.
23. Andreola M.L., et al. DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry. 40:2001;10087-10094.
24. Famulok M., et al. Intramers as promising new tools in functional proteomics. Chem. Biol. 8:2001;931-939.
25. Kusser W. Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution. J. Biotechnol. 74:2000;27-38.
26. Leva S., et al. GnRH binding RNA and DNA spiegelmers. A novel approach toward GnRH Antagonism. Chem. Biol. 9:2002;351-359.
27. Wlotzka B., et al. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc. Natl. Acad. Sci. U. S. A. 99:2002;8898-8902.
28. Drolet D.W., et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 17:2000;1503-1510.
29. Connolly D.T. Vascular permeability factor: a unique regulator of blood vessel function. J. Cell. Biochem. 47:1991;219-223.
30. Dvorak H.F., et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1995;1029-1039.
31. Gibbons G.H., Dzau V.J. The emerging concept of vascular remodeling. N. Engl. J. Med. 330:1994;1431-1438.
32. Takahashi T., et al. Renal microvascular assembly and repair: power and promise of molecular definition. Kidney Int. 53:1998;826-835.
33. Ostendorf T., et al. VEGF(165) mediates glomerular endothelial repair. J. Clin. Invest. 104:1999;913-923.
34. Floege J., et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. J. Pathol. 154:1999;169-179.
35. Ostendorf T., et al. The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J. Am. Soc. Nephrol. 13:2002;658-667.
36. Good P.D., et al. Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther. 4:1997;45-54.
37. Shi H., et al. RNA aptamers as effective protein antagonists in a multicellular organism. Proc. Natl. Acad. Sci. U. S. A. 96:1999;10033-10038.
38. Blind M., et al. Cytoplasmic RNA modulators of an inside-out signal-transduction cascade. Proc. Natl. Acad. Sci. U. S. A. 96:1999;3606-3610.
39. Konopka K., et al. Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs. J. Drug Target. 5:1998;247-259.
40. Konopka K., et al. Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication. Gene. 255:2000;235-244.
41. Yamamoto R., et al. A novel RNA motif that binds efficiently and specifically to the Ttat protein of HIV and inhibits the trans-activation by Tat of transcription in vitro and in vivo. Genes Cells. 5:2000;371-388.
42. Hamm J., Fornerod M. Anti-idiotype RNAs that mimic the leucine-rich nuclear export signal and specifically bind to CRM1/exportin 1. Chem. Biol. 7:2000;345-354.
43. Mayer G., et al. Controlling small guanine-nucleotide-exchange factor function through cytoplasmic RNA intramers. Proc. Natl. Acad. Sci. U. S. A. 98:2001;4961-4965.
44. Kolanus W., Seed B. Integrins and inside-out signal transduction: converging signals from PKC and PIP3. Curr. Opin. Cell Biol. 9:1997;725-731.
45. Shi H., et al. A specific RNA hairpin loop structure binds the RNA recognition motifs of the Drosophila SR protein B52. Mol. Cell. Biol. 17:1997;2649-2657.
46. Green L.S., et al. Aptamers as reagents for high-throughput screening. Biotechniques. 30:2001;1094-1100.
47. Famulok M. Bringing picomolar protein detection into proximity. Nat. Biotechnol. 20:2002;448-449.
48. Drolet D.W., et al. An enzyme-linked oligonucleotide assay. Nat. Biotechnol. 14:1996;1021-1025.
49. Jhaveri S., et al. In vitro selection of signaling aptamers. Nat. Biotechnol. 18:2000;1293-1297.
50. Hamaguchi N., et al. Aptamer beacons for the direct detection of proteins. Anal. Biochem. 294:2001;126-131.
51. Breaker R.R. Engineered allosteric ribozymes as biosensor components. Curr. Opin. Biotechnol. 13:2002;31-39.
52. Tang J., Breaker R.R. Rational design of allosteric ribozymes. Chem. Biol. 4:1997;453-459.
53. Jenne A., et al. Rapid identification and characterization of hammerhead-ribozyme inhibitors using fluorescence-based technology. Nat. Biotechnol. 19:2001;56-61.
54. Green L.S., et al. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry. 35:1996;14413-14424.
55. Bartel D.P., et al. HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell. 67:1991;529-536.